Forest’s Respiratory Pipeline: Can It Open The Revenue Airway?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
At a June 20 analyst meeting, Forest Labs discussed the potential for its respiratory pipeline, including the recently launched Daliresp and the yet-to-be approved aclidinium, which has a July PDUFA date.
You may also be interested in...
Settling In To The “New Normal”: Midway Through 2012, Another Banner Year For Drug Approvals Is Within Reach
The forecast for 2012 approvals looks sunny. FDA approved almost as many novel drugs in the first half of 2012 as it did in the first half of its record-breaking 2011 – and the agency has more than twice as many pending NME applications with user fee goals in the next six months as it had last year.
Panel Pushes For “Pragmatic” Post-Marketing Study, Head-To-Head Comparison For Forest’s Aclidinium
FDA’s Pulmonary-Allergy Drugs Advisory Committee suggests including endpoints that will help determine the value added by the COPD drug. Forest Labs says it is ready to discuss post-marketing options with FDA.
Positive COPD Data Allows Forest To File For Approval of Eklira in 2011
Forest Laboratories and Spain's Almirall report positive late-stage data for their COPD drug, paving the way for 2011 regulatory filings in the U.S. and EU.